Your browser doesn't support javascript.
loading
Left-Hand Side Exploration of Novel Bacterial Topoisomerase Inhibitors to Improve Selectivity against hERG Binding.
Hameed P, Shahul; Manjrekar, Praveena; Raichurkar, Anandkumar; Shinde, Vikas; Puttur, Jayashree; Shanbhag, Gajanan; Chinnapattu, Murugan; Patil, Vikas; Rudrapatana, Suresh; Sharma, Sreevalli; Kumar, C N Naveen; Nandishaiah, Radha; Madhavapeddi, Prashanti; Sriram, D; Solapure, Suresh; Sambandamurthy, Vasan K.
Afiliación
  • Hameed P S; AstraZeneca India Pvt. Ltd , Avishkar, Bellary Road, Bangalore-560024, India.
  • Manjrekar P; AstraZeneca India Pvt. Ltd , Avishkar, Bellary Road, Bangalore-560024, India.
  • Raichurkar A; AstraZeneca India Pvt. Ltd , Avishkar, Bellary Road, Bangalore-560024, India.
  • Shinde V; AstraZeneca India Pvt. Ltd , Avishkar, Bellary Road, Bangalore-560024, India.
  • Puttur J; AstraZeneca India Pvt. Ltd , Avishkar, Bellary Road, Bangalore-560024, India.
  • Shanbhag G; AstraZeneca India Pvt. Ltd , Avishkar, Bellary Road, Bangalore-560024, India.
  • Chinnapattu M; AstraZeneca India Pvt. Ltd , Avishkar, Bellary Road, Bangalore-560024, India.
  • Patil V; AstraZeneca India Pvt. Ltd , Avishkar, Bellary Road, Bangalore-560024, India.
  • Rudrapatana S; AstraZeneca India Pvt. Ltd , Avishkar, Bellary Road, Bangalore-560024, India.
  • Sharma S; AstraZeneca India Pvt. Ltd , Avishkar, Bellary Road, Bangalore-560024, India.
  • Kumar CN; AstraZeneca India Pvt. Ltd , Avishkar, Bellary Road, Bangalore-560024, India.
  • Nandishaiah R; AstraZeneca India Pvt. Ltd , Avishkar, Bellary Road, Bangalore-560024, India.
  • Madhavapeddi P; AstraZeneca India Pvt. Ltd , Avishkar, Bellary Road, Bangalore-560024, India.
  • Sriram D; AstraZeneca India Pvt. Ltd , Avishkar, Bellary Road, Bangalore-560024, India.
  • Solapure S; AstraZeneca India Pvt. Ltd , Avishkar, Bellary Road, Bangalore-560024, India.
  • Sambandamurthy VK; AstraZeneca India Pvt. Ltd , Avishkar, Bellary Road, Bangalore-560024, India.
ACS Med Chem Lett ; 6(7): 741-6, 2015 Jul 09.
Article en En | MEDLINE | ID: mdl-26191359
Structure-activity relationship (SAR) exploration on the left-hand side (LHS) of a novel class of bacterial topoisomerase inhibitors led to a significant improvement in the selectivity against hERG cardiac channel binding with concomitant potent antimycobacterial activity. Bulky polar substituents at the C-7 position of the naphthyridone ring did not disturb its positioning between two base pairs of DNA. Further optimization of the polar substituents on the LHS of the naphthyridone ring led to potent antimycobacterial activity (Mtb MIC = 0.06 µM) against Mycobacterium tuberculosis (Mtb). Additionally, this knowledge provided a robust SAR understanding to mitigate the hERG risk. This compound class inhibits Mtb DNA gyrase and retains its antimycobacterial activity against moxifloxacin-resistant strains of Mtb. Finally, we demonstrate in vivo proof of concept in an acute mouse model of TB following oral administration of compound 19.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: ACS Med Chem Lett Año: 2015 Tipo del documento: Article País de afiliación: India Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: ACS Med Chem Lett Año: 2015 Tipo del documento: Article País de afiliación: India Pais de publicación: Estados Unidos